1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
王昊天, 段晶晶, 侯辛未, 等. 间隔时间与内分泌治疗对双侧原发乳腺癌生物学指标及预后的影响. 中华医学杂志, 2016, 96(4): 281-284.
|
3. |
Ozturk A, Alco G, Sarsenov D, et al. Synchronous and metachronous bilateral breast cancer: A long-term experience. J Buon, 2018, 23(6): 1591-1600.
|
4. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
5. |
陈学燕, 李利亚, 万冬桂, 等. 双侧原发性乳腺癌两侧肿瘤病灶的差异性分析. 浙江医学, 2020, 42(1): 39-43.
|
6. |
Yoon TI, Kwak BS, Yi OV, et al. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. Breast Cancer Res Treat, 2019, 173(3): 657-665.
|
7. |
Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017, 35: 203-217.
|
8. |
Larson KE, Grobmyer SR, Valente SA. Evaluation of recurrence patterns and survival in modern series of young women with breast cancer. Breast J, 2018, 24(5): 749-754.
|
9. |
Huo D, Melkonian S, Rathouz PJ, et al. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer, 2011, 117(5): 907-915.
|
10. |
Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23 Suppl 7: vii11-vii19.
|
11. |
Robbins GF, Berg JW. Bilateral primary breast cancer; a prospective clinicopathological study. Cancer, 1964, 17: 1501-1527.
|
12. |
阚秀. 乳腺癌临床病理学. 北京: 北京医科大学, 中国协和医科大学联合出版社, 1993: 98-102.
|
13. |
Kridis WB, Sghaier S, Charfi S, et al. Ovarian cancer and breast metastases: a diagnostic dilemma. Arch Iran Med, 2020, 23(1): 53-55.
|
14. |
Shankar A, Roy S, Malik A, et al. Contralateral breast cancer: a clinico-pathological study of second primaries in opposite breasts after treatment of breast malignancy. Asian Pac J Cancer Prev, 2015, 16(3): 1207-1211.
|
15. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版). 中国癌症杂志, 2017, 27(9): 695-759.
|
16. |
American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017.
|
17. |
Tavassoli FA, Devilee P. WHO pathology & genetics tumours of the breast and femal genital organ. Lyon: IARC Press, 2003: 10.
|
18. |
Anwar SL, Prabowo D, Avanti WS, et al. Clinical characteristics and the associated risk factors of the development of bilateral breast cancers: A case-control study. Ann Med Surg (Lond), 2020, 60: 285-292.
|
19. |
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA, 2006, 295(21): 2492-2502.
|
20. |
聂琰, 谭博. Hepsin、MMP-7、CD147与三阴性乳腺癌微血管密度的相关性分析. 国际检验医学杂志, 2020, 41(15): 1863-1867.
|
21. |
Liang Q, Ma D, Gao RF, et al. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep, 2020, 10(1): 7648. doi: 10.1038/s41598-020-64523-1.
|
22. |
Ding L, Zhang Z, Xu Y, et al. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered, 2017, 8(4): 383-392.
|
23. |
Grumpelt AM, Ignatov A, Tchaikovski SN, et al. Tumor characteristics and therapy of elderly patients with breast cancer. J Cancer Res Clinl Oncol, 2016, 142(5): 1109-1116.
|
24. |
de Munck L, Schaapveld M, Siesling S, et al. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Res Treat, 2011, 129(1): 229-233.
|
25. |
Johansson ALV, Trewin CB, Hjerkind KV, et al. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer, 2019, 144(6): 1251-1261.
|
26. |
Baukloh JK, Reeh M, Spinoglio G, et al. Evaluation of the robotic approach concerning pitfalls in rectal surgery. Eur J Surg Oncol, 2017, 43(7): 1304-1311.
|
27. |
Chen X, He Y, Wang J, et al. Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients. Cancer Med, 2018, 7(7): 3066-3072.
|
28. |
Dhadlie S, Whitfield J, Hendahewa R. Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status. Int J Surg Case Rep, 2018, 53: 102-106.
|
29. |
Huber A, Seidler SJ, Huber DE. Clinicopathological characteristics, treatment and outcome of 123 patients with synchronous or metachronous bilateral breast cancer in a Swiss Institutional Retrospective Series. Eur J Breast Health, 2020, 16(2): 129-136.
|
30. |
Pan B, Xu Y, Zhou YD, et al. The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018). Cancer Med, 2019, 8(6): 2908-2918.
|
31. |
Ding S, Sun X, Lu S, et al. Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. Breast, 2021, 57: 71-79.
|
32. |
Kurzyński M, Mituś J, Kołodziej-Rzepa M, et al. Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries. Ginekol Pol, 2018, 89(5): 235-239.
|